United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Can pharma M&A survive Australia’s new national interest doctrine? Australia’s FIRB blocked Cosette’s $430M takeover of Mayne Pharma. Can foreign pharma buyers still close deals in this new national interest era? bySrinathNovember 25, 2025